Drugs / Measles-Mumps-Rubella Vaccine
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04357028 | Jul → Dec 2020 | COVID-19 | Kasr El Aini Hospital | Suspended | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06331702 | Mar 2024 → Feb 2025 | Japanese encephalitis, measles, mumps infectious disease, rubella | Liaoning Chengda Biotechnology CO., LTD | Completed | No outcome recorded |
| Phase 4 | NCT03183765 | Aug 2017 → Mar 2018 | common wart, plantar wart | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT02880865 | Oct 2016 → May 2017 | Japanese encephalitis, measles, mumps infectious disease, rubella | PATH | Completed | No outcome recorded |
| Phase 4 | NCT02153866 | Dec 2013 → May 2014 | Rotavirus infection | Sichuan Center for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04428359 | Jun 2020 → Jan 2021 | common wart | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles-Mumps-Rubella Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03183765 ↗ |
| Known as | MMR vaccine | “We are undertaking a study to evaluate and compare the safety and efficacy of 2 such immunotherapeutic agents namely, IL measles, mumps and rubella (MMR) vaccine versus IL...” NCT04428359 ↗ |
| Modality | Vaccine | “measles-mumps-rubella vaccine” NCT02153866 ↗ |
| Route | Subcutaneous | “0.5ml per dose, subcutaneous injection” NCT02153866 ↗ |